Silvana Bellini Vidor* and Emerson Antonio Contesini
Postgraduate Program in Veterinary Sciences, Universidade Federal do Rio Grande do Sul, Brasil
Submission: May 01, 2018; Published: May 09, 2018
*Corresponding author: Silvana Bellini Vidor, Postgraduate Program in Veterinary Sciences, Universidade Federal do Rio Grande do Sul. Av. Bento Gonçalves, 9090 - Agronomia - 91540-000, Porto Alegre, RS- Brasil, Tel: Email: email@example.com
How to cite this article: Silvana B V,Emerson A C. Stem Cells to Improve the Wound Healing. J Head Neck Spine Surg. 2018; 3(1): 555601. DOI: 10.19080/JHNSS.2018.03.555601
The cellular therapy using Mesenchymal Stem Cells, specially its two subtypes - Bone-marrow Mesenchymal Stem Cells and Adipose Derived Stem Cells - can benefit by virtue of the possibility of differentiating in specialized cells that secrete and suppress growing factors and cytokines necessary in the lesion niche. When attracted by the pro-inflammatory sinalization of the lesion, they act using the paracrine signaling, decreasing the inflammation, increasing the angiogenesis and the cell migration and proliferation. The development in the researches regarding the association of the application of MSCs, with reconstructive surgery practices, leads to effective future results that can bring more benefits to the clinic practice of this field. This paper has the objective of briefly reviewing the literature about the usage of MSCs and its subtypes, the ADSCs, to improve the skin cicatrization.
Mesenchymal stem cells (MSCs) were first described by Friedenstein et al. [1,2]. MSCs are heterogeneous cell populations, called multipotent adult cells or somatic stem cells [3,4], capable of differentiation in most cell types in order to maintain and repair the organism. They are resident in different organs and tissues such as adipose tissue [4,5], bone marrow, umbilical cord, amniotic membrane [2,4], kidneys, liver, spleen, lungs, pancreas, tendons, synovial membranes, placenta, amniotic fluid and dental pulp . The International Society for Cellular Therapy proposed three minimal criteria for defining MSCs:
a) Plastic adherence;
b) Positive expression (greater than 95% of the cell population) for CD105, CD73 and CD90 markers and negative, (maximum 2% of the population) for CD45, CD34, CD14, CD11b, CD79a, CD19 and Human leukocyte antigen (HLA-DR) surface molecules, and
c) Ability to differentiate into osteoblasts, adipocytes and chondroblasts under standard in vitro differentiating conditions [2,6].
Later, others researchers complemented this characterization with new markers: CD13, CD44, CD54, 106 and Stro-1  and the presentation of fibroblast cellular morphology [3,4].
MSCs have a great potential to the tissue repairment and regeneration in reconstructive plastic surgery, preventing ischemic lesions in skin flaps [7-14] and in skin grafts [15,16]. MSCs are capable of reducing severe atrophy, retraction, fibrosis and ulceration skin signals, caused by radiotherapy [17,18]. Combined with the lipoinjection in face and body defects and in rejuvenating esthetic treatments, MSCs raise in 35% the survival rate and the microvasculature from the injected fat . Also, diabetic patients with ischemic wounds show greater survival rates and lower number of amputations in affected limbs, when treated with Adipose derived stem cells (ADSCs) . The MSCs improved the skin healing at induced burns in rats [20,21]. In dermatology, the MSCs are being clinically used for inflammatory diseases [22-28], Graft-Versus-Host Disease [23,25], Chrown Disease , Systemic Sclerosis, Lupus or dermatomyositis [24,28,30].
When compared with the usage of Growing Factors, that like any drug has a limited half-life, the cellular therapy using MSCs, specially in its two subtypes - the Bone-Marrow Mesenchymal Stem Cells (BM-MSCs) and ADSCs - can bring greater benefits because of: their expansion capacity in cellular culture; stable phenotypic expression; and possibility of differentiating in specialized cells, that secrete and suppress cytokines and growing
factors in the injury [13,31-33]. However, long expansion periods of the cellular culture, to achieve effective therapeutic doses, raise the possibility of infection from the host. Because of that, the ADSCs still have to be heavily studied to the application in the clinic routine . This way, this study has as objective briefly review the literature about the usage of MSCs and its subtypes, the ADSCs, to improve the skin healing.
The MSCs are capable to answer and adjust their functions, when exposed to cells or typical factors of the lesion environment [33,34]. They have an attraction capacity to the inflammation areas [33-35] or tumors, because of the molecules CCL21 or HMGB1, known as homing. In case of lacking of this signalization, they are attracted in order of preference to the lungs, liver and spleen . The MSCs show chemotaxis in vitro by the Stromal Cell-Derived Factor (SDF1), Platelet-Derived Growth Factor (PDGF), Insulin-Like Growth Factor-1, Interleukin-8 (1L-8) and Tumor Necrosis Factor-α (TNFα). In murine models, the MSCs used in the systemic administration are capable of getting into the damaged tissues [14,34,36].
The MSCs act, in many levels, in the three healing phases: inflammatory, proliferative and remodeling phase. Current studies indicate that the differentiation of the MSCs, that contributed to the tissue regeneration, is limited by the small survival rate of these cells in the damaged area. However, the paracrine signaling to the cells from the injury is the main mechanism of the MSCs, reducing the inflammation, stimulating the angiogenesis and inducing the cell migration and proliferation [33,37]. Nevertheless, other authors suggest that the differentiation of the MSCs in keratinocytes and endothelial cells have the same function as the paracrine signaling to accelerate the neovascularization and the reepithelialization of wounds  (Figure 1 & 2).
Some studies suggest that immunosuppressive potential is the same of both types of MSCs, ADSCs and BM-MSCs, in an inflammatory environment. Their local administration inhibited the T cells recruitment and proliferation [37-41] and decrease Interferon-γ (lFNγ),Tumor Necrosis Factor-α (TNFα), 1L-6 and IL-1β expression in the skin grafts [39-41]. In the inflammatory phase (one to three days), the expression of anti-inflammatory cytokines 1L-4 and 1L-10 is increased while 1L-2 pro- inflammatory cytokines, TNF-α and 1FN-γ are decreased, causing less local inflammatory reaction [37,42]. MSCs can also regulate macrophage activation and convert phenotype expression of M1 macrophages to M2 anti-inflammatory macrophages [39-41], which accelerates the wound healing. Additionally, MSCs act over the innate immunity to prevent the rejection of transplanted allografts, inhibiting the complement system activation . The decrease of TFN-α also helps the reepithelialization after the proliferation phase . The antimicrobial action from the MSCs are also important to limit the infection occurrence .
With the utilization of cell therapy in the proliferative phase (14 days) the production of important growth factors is increased: Vascular Endothelial Growth Factor (VEGF), Basic Fibroblast Growth Factor (bFGF) [32,37,42,43], Epidermal Growth Factor (EGF), Keratinocyte Growth Factor (KGF), Hepatocyte Growth Factor (HGF), Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-beta (TGF-β). Through their paracrine action, the MSCs raise the migration and proliferation of keratinocytes, endothelial and epithelial cells. The fibroblasts proliferation is also enhanced, as well as the blood vessels' formation. This way, there is a better growing of a more vigorous granulation tissue [33,37,42,43]. The angiogenesis is a very important factor to the wound's healing, and the VEGF and the Fibroblast Growth Factor (FGF) are very important angiogenic factors .
Through the paracrine signaling, from the MSCs in the remodeling phase (21 days to one year), the fibroblasts produce collagen fibers in greater quantity and density, generating an increase in wound tensile strength [37,42,43]. At the same time, there is a smaller wound contraction and increased matrix-metalloproteinases production, that control the collagen deposition exacerbation, improving the aesthetic result and keeping the skin's function [33,42,43]. MSCs also contribute to the scar's appropriate remodeling with the increased secretion of VEGF and HGF, the adequate balance between TGF-β1 and TGF-β3  and the increase of bFGF and TGF-β which inhibit the Alpha-Smooth Muscle Actin (α-SMA) expression, responsible for myofibroblast phenotype .
Studies indicate that there is also the possibility of using BM-MSCs and ADSCs to protect the damaged tissues caused by the 1schemia-Reperfusion 1njury (1R1) and to decrease the dysfunction of organs undergoing ischemia. The ADSCs are able to protect axial flaps from the 1R1 with results as satisfactory as the ones obtained in procedures without ischemia, because of the improvement in the angiogenic response and the blood perfusion elevation . Many studies use the ADSCs to prevent ischemic injuries in skin flaps [7-14], as others [15,16] used them to improve the quality of skin grafts.
The MSCs - both BM-MSCs and ADSCs - are capable to answer and module their functions, when exposed to cells or typical factors of the lesion environment, attracted by the cell signaling to the inflammation areas. The researches developed till the moment point the paracrine signaling as the main mechanism from the MSCs, decreasing the inflammation, benefiting the angiogenesis and inducing the cell migration and proliferation in the damaged area. The progress on the researches about the association of MSCs with reconstructive surgery practices indicates good and productive results, which can benefit the clinical practice in this field.